FDA Considers New Regulatory Pathways For Some Cellular Products
Executive Summary
The US agency is re-evaluating its criteria for certain human cells, tissues and cellular and tissue-based products (HCT/Ps) that are not ideally regulated as BLAs. A 2014 guidance on cord blood products could serve a template, industry suggests.
You may also be interested in...
MDUFA V Passed By US House Health Subcommittee
The user fee package was among several health-related bills that the subcommittee took up on Wednesday.
FDA Aims To Clarify Human Cell/Tissue Regulation With Upcoming Meeting, Guidance Documents
FDA announced an April hearing to discuss four open draft guidance documents clarifying the regulation of human cells, tissues, or cellular or tissue-based products.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.